Recent Quotes
View Full List
My Watchlist
Agios Pharmaceuticals, Inc. - Common Stock
Aspen Neuroscience, Inc. - Common Stock
BeLive Holdings - ordinary shares
Biddance AI Systems, Inc. - Class A Ordinary Share
Cannabis Global Inc
Capital Group Conservative Equity ETF
Capstone Holding Corp. - Common Stock
Chaince Digital Holdings Inc. - American Ordinary Shares
Corgi AMD 2x Daily ETF
Corgi MU 2x Daily ETF
Defiance Daily Target 2X Long IREN ETF
Defiance Daily Target 2X Long SOFI ETF
Defiance Daily Target 2X Short AMD ETF
Defiance Daily Target 2x Long OKLO ETF
Direxion Daily AMD Bull 2X ETF
Direxion Daily S&P Oil & Gas Exp. & Prod. Bear 2X ETF
Direxion Technology Bear 3X ETF
Evernorth Holdings Inc. - Warrants
Evio Inc
Evolution Metals & Technologies Corp. - Common Stock
Femasys Inc. - Common Stock
Gold
Guidewire Software, Inc. Common Stock
Illumina, Inc. - Common Stock
Leverage Shares 2X Long FPS Daily ETF
Leverage Shares 2x Long FIG Daily ETF
Liminatus Pharma, Inc. - Class A Common Stock
Ludwig Enterprises Inc
MicroSectors -3x Short Semiconductor ETNs
OraSure Technologies, Inc. - Common Stock
Psyence Biomedical Ltd. - Common Shares
QVC Group, Inc. - Common Stock
Rush Street Interactive, Inc. Class A Common Stock
Sanwire Corp
Scage Future - American Depositary Shares
Spyre Therapeutics, Inc. - Common Stock
Stem, Inc. Class A Common Stock
T-REX 2X Inverse CRCL Daily Target ETF
T-REX 2X Long SNOW Daily Target ETF
T-REX 2X Long TE Daily Target ETF
Toshiba Corp
Tradr 2X Long APP Daily ETF
Tradr 2X Long CLSK Daily ETF
Trio-Tech International - Common Stock
Webstar Technology Group Inc
iShares Russell Top 200 Value ETF
Edit Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
InMode Ltd. - Ordinary Shares
(NQ:
INMD
)
13.70
UNCHANGED
Delayed Quote
Updated: 4:00 PM EST, Nov 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about InMode Ltd. - Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
InMode (NASDAQ:INMD) Q2 Revenue Inline, EPS Beats; Shares Dip 2.5%
↗
August 05, 2026
Via
Chartmill
Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One
August 04, 2026
Issued on behalf of Conexeu Sciences Inc. (Nasdaq: CNXU)
From
American News Group
Via
GlobeNewswire
Securities Fraud Investigation Into InMode Ltd. (INMD) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
July 02, 2026
From
Glancy Prongay Wolke & Rotter LLP
Via
Business Wire
InMode (NASDAQ:INMD) Slumps After Q1 2026 Earnings Miss Overshadows Revenue Beat
↗
May 06, 2026
Via
Chartmill
Topics
Earnings
InMode Ltd. (NASDAQ:INMD) Reports Q4 2025 Earnings Beat Amid Revenue Shortfall
↗
February 10, 2026
Via
Chartmill
Topics
Earnings
InMode Ltd (NASDAQ:INMD) Passes Key Peter Lynch GARP Investment Filters
↗
January 23, 2026
Via
Chartmill
INMD Stock Draws Investor Attention On Q4 Financial Update
↗
January 09, 2026
Via
Stocktwits
InMode Ltd. (NASDAQ:INMD): A Peter Lynch-Style GARP Investment Candidate
↗
December 31, 2025
Via
Chartmill
InMode Ltd. (INMD) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
July 02, 2026
From
Law Offices of Howard G. Smith
Via
Business Wire
Securities Fraud Investigation Into InMode Ltd. (INMD) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
July 01, 2026
From
The Law Offices of Frank R. Cruz
Via
Business Wire
The Aesthetics Giants Just Confirmed “Ozempic Face” Is Real — and a Newly Public Regenerative Player Wants to Compete for It
June 25, 2026
From
Biotech Insider
Via
GlobeNewswire
There are notable gap-ups and gap-downs in today's session.
↗
June 24, 2026
Via
Chartmill
Earnings Scheduled For November 5, 2025
↗
November 05, 2025
Via
Benzinga
Earnings Scheduled For July 30, 2025
↗
July 30, 2025
Via
Benzinga
After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast Instead
May 27, 2026
Issued on behalf of Conexeu Sciences Inc.
From
Biotech Insider
Via
GlobeNewswire
InMode (INMD) Q1 2026 Earnings Call Transcript
↗
May 06, 2026
InMode (INMD) Q1 2026 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
InMode (INMD) Stock Slips As Board Ends Review
↗
February 23, 2026
Shares of InMode Ltd (NASDAQ: INMD) are trading lower Monday morning after the Israeli medical technology company said a special independent transaction committee has ended its strategic review without...
Via
Benzinga
InMode (INMD) Q4 2025 Earnings Call Transcript
↗
February 10, 2026
InMode (INMD) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
InMode Shares Are Rallying After Hours – What’s The Takeover Offer?
↗
January 28, 2026
Steel Partners said it is pursuing an acquisition of 51% of InMode’s outstanding shares.
Via
Stocktwits
INMD Stock Jumped Nearly 13% Today – What’s Powering The Rally?
↗
January 26, 2026
According to a Calcalist report, the company is set to go private after a $1.1 billion acquisition by a fund.
Via
Stocktwits
Topics
Artificial Intelligence
InMode Ltd. (NASDAQ:INMD) Emerges as a Peter Lynch-Style GARP Candidate
↗
December 08, 2025
InMode stock aligns with Peter Lynch's GARP strategy, showing strong earnings growth, high profitability, zero debt, and an undervalued PEG ratio for long-term investors.
Via
Chartmill
InMode Ltd (NASDAQ:INMD): A Peter Lynch-Style GARP Investment Candidate
↗
November 15, 2025
InMode Ltd fits Peter Lynch's GARP strategy with strong earnings, zero debt, and a low PEG ratio, making it a compelling long-term investment candidate.
Via
Chartmill
InMode (INMD) Q3 2025 Earnings Call Transcript
↗
November 05, 2025
InMode (INMD) Q3 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
World Trade
InMode Ltd (NASDAQ:INMD) Tops Q3 2025 Earnings and Revenue Estimates
↗
November 05, 2025
InMode Q3 2025 earnings beat estimates on revenue and EPS, showcasing strong profitability and demand for its medical aesthetic products.
Via
Chartmill
Topics
Earnings
INMODE LTD (NASDAQ:INMD) Appears to Fit Peter Lynch's Investment Criteria
↗
October 25, 2025
InMode (INMD) aligns with Peter Lynch's GARP strategy, showing strong earnings growth, zero debt, and a low PEG ratio for long-term value.
Via
Chartmill
INMODE LTD (NASDAQ:INMD): A Peter Lynch-Style GARP Investment
↗
October 04, 2025
INMODE LTD (INMD) aligns with Peter Lynch's GARP strategy, showing strong earnings growth, zero debt, and an undervalued PEG ratio for long-term investors.
Via
Chartmill
InMode Ltd. (NASDAQ:INMD) Embodies Peter Lynch's GARP Strategy with Strong Financials and Undervalued Growth
↗
September 13, 2025
InMode (INMD) is a debt-free medical aesthetics stock with strong profitability and a low P/E ratio, fitting Peter Lynch's GARP strategy for growth at a reasonable price.
Via
Chartmill
InMode Ltd (NASDAQ:INMD) Embodies Peter Lynch's GARP Philosophy with Strong Growth and Undervalued Metrics
↗
August 23, 2025
Discover InMode (INMD), a top GARP stock per Peter Lynch's strategy. Strong earnings growth, zero debt, and a low PEG ratio highlight its value in the medical aesthetics sector.
Via
Chartmill
INMODE LTD (NASDAQ:INMD): A Peter Lynch-Style GARP Investment with Strong Fundamentals and Undervalued Growth Potential
↗
August 02, 2025
Peter Lynch’s GARP strategy highlights INMODE LTD (INMD) as a strong candidate with steady earnings, low debt, and undervalued growth potential.
Via
Chartmill
InMode Ltd (NASDAQ:INMD) Reports Mixed Q2 2025 Results: Revenue Miss but EPS Beat Drives Pre-Market Gains
↗
July 30, 2025
InMode's Q2 2025 earnings show mixed results: revenue missed estimates at $95.6M, but EPS beat at $0.47. Shares rose 3.4% pre-market on strong profitability.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.